Plant Name: Aristolochia elegans
Taxonomic Information:
Plant ID: NPO22568
Plant Latin Name: Aristolochia elegans
Taxonomy Genus: Aristolochia
Taxonomy Family: Aristolochiaceae
Plant External Links:
NCBI TaxonomyDB:
143780
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| CDC25B; | |
| RECQL; TDP1; BLM; GLO1; HPGD; AKR1B10; ALOX12; HSD17B1; AKR1B1; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| TOP2A; | |
| TEK; PIM1; MET; AXL; KDR; SRC; FLT3; CDK1; EGFR; NUAK1; INSR; IGF1R; AURKB; CSNK2A1; | |
| CA12; CA7; CA4; | |
| PPARA; | |
| RORC; | |
| ESR2; ESR1; | |
| NR1H4; | |
| KDM4E; | |
| F10; F2; | |
| BACE1; | |
| MMP12; | |
| HIF1A; | |
| FUT7; | |
| SLC22A6; | |
| SMAD3; LMNA; FABP5; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.088E-08 | 4.084E-06 | AXL, EGFR, F10, INSR, MET, NOX4, SRC, TEK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 6.747E-08 | 1.814E-05 | AURKB, AXL, BLM, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.599E-07 | 3.627E-05 | AKR1B1, APEX1, AURKB, BLM, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, FABP5, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, NR1H4, NUAK1, PIM1, POLB, PPARA, RECQL, RORC, SMAD3, SRC, TOP2A |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.176E-07 | 4.738E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.331E-07 | 6.843E-05 | BLM, CA12, CA4, CA7, ESR1, ESR2, GLO1, L3MBTL1, MMP12, NR1H4, PPARA, RORC, SMAD3 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 6.250E-07 | 1.106E-04 | ESR1, ESR2, NR1H4, PIM1, PPARA, RORC, SRC |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 6.624E-07 | 1.127E-04 | CYP1A1, HIF1A, LMNA, NOX4, PPARA, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 8.188E-07 | 1.351E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| MF | Unclassified; | GO:0004872; receptor activity | 8.170E-07 | 1.351E-04 | AXL, EGFR, ESR1, ESR2, F2, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TEK |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.324E-06 | 2.017E-04 | AXL, CSNK2A1, EGFR, ESR1, PPARA, RORC, SRC, TOP2A |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.813E-06 | 2.685E-04 | EGFR, INSR, KDR |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.831E-06 | 2.694E-04 | ESR1, ESR2, NR1H4, PPARA, RORC, SRC |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.462E-06 | 3.330E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 4.287E-06 | 5.396E-04 | ACHE, EGFR, HSD17B1, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.542E-06 | 5.587E-04 | ESR1, ESR2, HSD17B1, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 6.095E-06 | 7.253E-04 | CDK1, ESR1, ESR2, NR1H4, PPARA, RORC |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.177E-06 | 7.310E-04 | AKR1B1, AKR1B10, CYP1A1, CYP1B1, ESR1, HSD17B1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 6.684E-06 | 7.784E-04 | AXL, HIF1A, HSPA1A, MMP12 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.961E-06 | 8.935E-04 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.961E-06 | 8.935E-04 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.701E-06 | 1.046E-03 | CA12, CA4, CA7 |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.221E-05 | 1.255E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP12, PPARA, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.801E-05 | 1.720E-03 | CDK1, EGFR, IGF1R, INSR |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.872E-05 | 1.757E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.880E-05 | 1.757E-03 | F2, NR1H4, PPARA, SMAD3, TEK |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 2.218E-05 | 1.988E-03 | AKR1B1, AKR1B10, HPGD, HSD17B1, HSD17B10 |
| BP | GO:0008152; metabolic process | GO:0045893; positive regulation of transcription, DNA-templated | 3.018E-05 | 2.537E-03 | BLM, EGFR, ESR1, ESR2, HIF1A, INSR, MET, MMP12, NR1H4, PPARA, RORC, SMAD3, SRC, TOP2A |
| BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 3.237E-05 | 2.680E-03 | ESR1, ESR2, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 3.395E-05 | 2.747E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.421E-05 | 2.749E-03 | ACHE, BLM, CSNK2A1, EGFR, ESR1, ESR2, FLT3, HPGD, IGF1R, KDR, L3MBTL1, MET, SLC22A6, SMAD3, TOP2A |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 3.719E-05 | 2.977E-03 | F2, FLT3, KDR, TEK |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.770E-05 | 3.007E-03 | AKR1B1, AKR1B10, ALOX12, APEX1, CYP1A1, CYP1B1, HPGD, HSD17B1, HSD17B10, KDM4E, NOX4 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.759E-05 | 3.611E-03 | ESR1, ESR2 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.871E-05 | 3.657E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 5.359E-05 | 3.955E-03 | ACHE, EGFR, HIF1A, MMP12, NR1H4, SRC |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 5.903E-05 | 4.270E-03 | ALOX12, CYP1A1, CYP1B1, GLO1, HIF1A, HPGD, NR1H4, PPARA |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 6.750E-05 | 4.696E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 6.823E-05 | 4.731E-03 | AKR1B1, CYP1B1, F2, FLT3 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 7.574E-05 | 5.203E-03 | AXL, IGF1R, INSR |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 7.614E-05 | 5.214E-03 | ALOX12, CYP1B1, HIF1A, KDR, TEK |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 7.917E-05 | 5.321E-03 | BLM, RECQL |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 8.398E-05 | 5.571E-03 | FLT3, SRC, TEK |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 1.005E-04 | 6.383E-03 | APEX1, EGFR, ESR1, ESR2, HIF1A, NR1H4, PPARA, RORC, SMAD3, TDP1 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.018E-04 | 6.447E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.022E-04 | 6.450E-03 | CSNK2A1, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.122E-04 | 6.920E-03 | HIF1A, PPARA, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.122E-04 | 6.920E-03 | INSR, PPARA, SRC |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.185E-04 | 7.250E-03 | ALOX12, HPGD |
| BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 1.228E-04 | 7.427E-03 | CDK1, HIF1A, INSR |
| BP | GO:0008283; cell proliferation | GO:0050679; positive regulation of epithelial cell proliferation | 1.390E-04 | 8.180E-03 | EGFR, HIF1A, KDR, MMP12, TEK |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.428E-04 | 8.356E-03 | AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.459E-04 | 8.502E-03 | CA12, CA4, CA7 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.460E-04 | 8.502E-03 | EGFR, ESR1, HIF1A, MET, SMAD3, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.656E-04 | 9.369E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.656E-04 | 9.369E-03 | FLT3, KDR |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.656E-04 | 9.369E-03 | EGFR, ESR1 |
| MF | GO:0003824; catalytic activity | GO:0043140; ATP-dependent 3'-5' DNA helicase activity | 1.656E-04 | 9.369E-03 | BLM, RECQL |
| BP | GO:0008152; metabolic process | GO:0016101; diterpenoid metabolic process | 1.675E-04 | 9.423E-03 | AKR1B10, CYP1A1, CYP1B1, EGFR |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 1.735E-04 | 9.737E-03 | CDK1, CSNK2A1, EGFR, F2, HIF1A, LMNA, NPSR1, NR1H4, SMAD3, SRC |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.742E-04 | 9.753E-03 | CDK1, EGFR, F2, SMAD3 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.250E-09 | 1.625E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.518E-07 | 1.636E-05 | HSD17B1, INSR, CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.344E-06 | 5.653E-05 | SRC, KDR, HIF1A, ESR1, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.739E-06 | 5.653E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 6.726E-06 | 1.663E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.674E-06 | 1.663E-04 | SRC, ESR1, EGFR, ESR2, HSPA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.315E-06 | 1.730E-04 | INSR, TEK, HIF1A, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.646E-05 | 4.740E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.449E-05 | 4.740E-04 | FLT3, MET, HIF1A, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.372E-04 | 3.653E-03 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.309E-04 | 2.729E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.513E-04 | 6.104E-03 | SMAD3, FLT3, HIF1A, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 4.902E-04 | 4.902E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 7.281E-04 | 6.104E-03 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 8.690E-04 | 6.646E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.324E-03 | 8.605E-03 | PIM1, CYP1B1, MET, EGFR, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 9.853E-04 | 7.021E-03 | MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.455E-04 | 5.066E-03 | HSD17B1, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.026E-03 | 7.021E-03 | SRC, ESR1, ESR2 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.302E-05 | 2.116E-04 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.513E-03 | 9.367E-03 | HPGD, FLT3, MET, IGF1R |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; F2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; INSR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| NA: NA | Christmas disease | NA | F10; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; INSR; EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; TEK; EGFR; SRC; F2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; INSR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
| NA: NA | Haemophilia B | NA | F10; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; F2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; INSR; EGFR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; TEK; EGFR; SRC; F2; CDC25B; |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
